Palatin Technologies (PTN) Registration Filing summary

Company overview and business model

• Focuses on developing first-in-class medicines targeting melanocortin receptor systems for diseases with unmet medical need and commercial potential.

• Primary development areas include obesity, male sexual dysfunction, and inflammatory/autoimmune diseases (ocular, gut, kidney).

• Commercial product Vyleesi (bremelanotide) for HSDD in premenopausal women was sold to Cosette in December 2023; company now funds R&D through proceeds and partnerships.

• Pipeline includes multiple clinical and preclinical programs, with several Phase 2 and 3 trials ongoing or planned for obesity, ED, dry eye disease, and ulcerative colitis.

• Business strategy emphasizes internal development, strategic alliances, and leveraging licensing agreements for funding.

Financial performance and metrics

• Qualified as a "smaller reporting company" with annual revenue under $100 million and market value under $560 million as of the last fiscal year.

• Received $6.1 million in gross proceeds from warrant exercises in June 2024.

• Audit report notes recurring operating losses and negative cash flows, raising substantial doubt about ability to continue as a going concern without additional funding.

Use of proceeds and capital allocation

• Will not receive proceeds from resale of shares by selling stockholders; will receive up to $9.1 million if all inducement warrants are exercised for cash.

• Proceeds from warrant exercises are intended to support ongoing product development and operations.

• No dividends anticipated; earnings to be retained for business use.